INFU: Volatility Compression detected on 25 Feb 2026

INFU is forming a volatility compression pattern at $8.60, near 52-week highs (22.1% below $11.04). Structure score of 15/15 and volume ratio of 1.24x suggest tight consolidation with above-average participation. Breakout score of 13/13 indicates strong directional potential, though resistance sits just 2 cents above current price at $8.61. The 75.38% win probability reflects favorable technical conditions for directional movement. Bollinger Band position of 1.019 shows price near upper bands, and ATR of 0.37 points to controlled volatility ready for expansion.

InfuSystem reported solid 7% revenue growth in 2025 with full-year adjusted EBITDA expanding 24% to $31.5 million and strong operating cash flow of $7.1 million. The company guides 2026 revenue growth of 6–8% despite a $7.1 million contract hit from restructuring its largest biomedical services customer contract, which reduced revenue starting in January 2026. The restructuring is expected to significantly improve margins on the continuing business. Analyst consensus is bullish: analysts provide a median forecast of $15.00 with 78.8% upside potential, supported by 5 Buy ratings and 0 Sell ratings. The company's IT systems upgrade is expected to be completed in Q1 2026. The earnings reaction on February 24, 2026 sparked the 13.16% one-week gain, positioning INFU for continuation.

A successful volatility compression breakout would target $8.98 (conservative target), representing 4.4% upside from current levels. Volume confirmation should sustain above 145k shares (20-day average) during breakout acceleration. RSI at 59.21 provides room to trend higher toward overbought territory without signal invalidation. The pattern fails if price closes below key support at $7.32 (15% downside risk), which would negate the technical setup. At current 75.38% win probability, the setup suggests more breakouts succeed than fail, with MACD histogram positive at 0.0833 confirming upside momentum initiation.

Earnings risk looms with next report scheduled for March 18, 2026—just 21 days away. Revenue headwinds of $7.1 million from contract restructuring began in January 2026, which may pressure Q1 guidance or temper investor enthusiasm if execution lags expectations. Beta of 1.04 exposes the stock to broad market volatility. While RSI at 59.21 is neutral, elevated valuations (P/E of 34.46 forward) leave limited margin for earnings misses. The IT systems upgrade through Q1 adds operational execution risk. IT upgrade costs are expected to decrease significantly after Q1 2026, but any project delays could pressure margins near-term and trigger profit-taking before the pattern completes.